Impact of Cannabis-Based Medicine on Alzheimer’s Disease by Focusing on the Amyloid β- Modifications: A Systematic Study

 “Deposition of amyloid-beta (Aβ) peptide in the brain is the leading source of the onset and progression of Alzheimer’s disease (AD). Recent studies have suggested that anti-amyloidogenic agents may be a suitable therapeutic strategy for AD.

Aim: The current review was proposed to address the beneficial effects of cannabis-based drugs for the treatment of AD, focusing primarily on Aβ modifications.

Result: A total of 17 studies were identified based on the inclusion criteria; however, nine studies qualified for this systematic review. The maximum and minimum cannabis dosages, mostly CBD and THC in animal studies, were 0.75 and 50 mg/kg, respectively. Cannabis (CBD and THC) was injected for 10 to 21 days. The findings of the 9 articles indicated that cannabis-based drugs might modulate Aβ modifications in several AD models.

Conclusion: Our findings establish that cannabis-based drugs inhibited the progression of AD by modulating Aβ modifications.”

https://pubmed.ncbi.nlm.nih.gov/32640965/

https://www.eurekaselect.com/183559/article

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Leave a Reply

Your email address will not be published. Required fields are marked *